Volume 68, Issue 2, Pages (August 2005)

Slides:



Advertisements
Similar presentations
Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages
Advertisements

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.
Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares D.J. Birmingham,
Kamyar Kalantar-Zadeh  Kidney International 
Volume 58, Issue 5, Pages (November 2000)
Volume 68, Issue 4, Pages (October 2005)
Volume 54, Issue 2, Pages (August 1998)
Biomarkers of lupus nephritis determined by serial urine proteomics
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Volume 93, Issue 1, Pages (January 2018)
Stem cells for kidney repair: useful tool for acute renal failure?
Volume 94, Issue 4, Pages (October 2018)
Volume 81, Issue 4, Pages (February 2012)
Volume 63, Issue 6, Pages (June 2003)
Subclinical rejection in renal transplants is associated with low serum mannose-binding lectin levels  Meritxell Ibernon, Francesc Moreso, Daniel Serón 
Volume 60, Issue 2, Pages (August 2001)
Continuous renal replacement therapy in the critically ill patient
Mycophenolate therapy of SLE membranous nephropathy
Gene Copy-Number Variation and Associated Polymorphisms of Complement Component C4 in Human Systemic Lupus Erythematosus (SLE): Low Copy Number Is a.
Volume 56, Issue 2, Pages (August 1999)
Francesco Paolo Schena  Kidney International 
Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real?  S. Andrulli, S. Di Filippo, F. Locatelli 
Kamyar Kalantar-Zadeh  Kidney International 
Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy?  Fu L. Luan, Diane E. Steffick,
Volume 68, Issue 4, Pages (October 2005)
Volume 72, Issue 7, Pages (October 2007)
Comorbidity and confounding in end-stage renal disease
Volume 74, Issue 3, Pages (August 2008)
Lipid redistribution in renal dysfunction
Volume 70, Issue 11, Pages (December 2006)
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
The epidemiology of chronic kidney disease
Volume 61, Issue 4, Pages (April 2002)
Volume 70, Issue 12, Pages (December 2006)
The Case ∣ Fever, rash, and positive Ehrlichia antibodies
Blood pressure targets in hemodialysis patients
Response to ‘Hepcidin levels in patients with renal disease’
Volume 76, Issue 6, Pages (September 2009)
Volume 87, Issue 1, Pages (January 2015)
Biomarkers of lupus nephritis determined by serial urine proteomics
The third World Kidney Day: Looking back and thinking forward
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Elevated risk of stroke among patients with end-stage renal disease
Alternate-day dialysis may be needed for hemodialysis patients
Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes  J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.
V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen 
Shannon D. Smith, Marcia A. Wheeler, Marc I. Lorber, Robert M. Weiss 
Volume 78, Issue 5, Pages (September 2010)
Volume 57, Issue 5, Pages (May 2000)
Volume 76, Issue 12, Pages (December 2009)
Long-term survival in renal transplant recipients with graft function
Daily nocturnal home hemodialysis
The valuable contribution of observational studies to nephrology
The Danish Renal Biopsy Register
Volume 63, Issue 6, Pages (June 2003)
Volume 56, Issue 2, Pages (August 1999)
Is complement a target for therapy in renal disease?
Volume 70, Issue 3, Pages (August 2006)
Volume 86, Issue 2, Pages (August 2014)
Volume 70, Issue 5, Pages (September 2006)
H.J. Chin, H. Ro, H.J. Lee, K.Y. Na, D.-W. Chae  Kidney International 
Volume 70, Issue 10, Pages (November 2006)
The International Pediatric Peritonitis Registry: Starting to walk
S. Dmitrienko, A. Yu, R. Balshaw, R.J. Shapiro, P.A. Keown 
Rajni Singhal, Janet E. Hux, Shabbir M H Alibhai, Matthew J. Oliver 
Kevin C. Abbott, Robert J. Oglesby, Lawrence Y. Agodoa 
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Current standard of care treatment protocols for LN induction therapy.
Presentation transcript:

Volume 68, Issue 2, Pages 747-759 (August 2005) Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy  Brad H. Rovin, Yuxiao Tang, Junfeng Sun, Haikady N. Nagaraja, Kevin V. Hackshaw, Linda Gray, Robert Rice, Daniel J. Birmingham, Chack-Yung Yu, D.A.N. N. Spetie, A.M.Y. Aziz, L.E.E. A. Hebert  Kidney International  Volume 68, Issue 2, Pages 747-759 (August 2005) DOI: 10.1016/S0085-2538(15)50895-8 Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Mean daily prednisone dose ± 1 SD in the renal and nonrenal systemic lupus erythematosus (SLE) patients during study follow-up. The difference in mean prednisone dose between the renal and nonrenal patients is significant,P < 0.001. Kidney International 2005 68, 747-759DOI: (10.1016/S0085-2538(15)50895-8) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Fever trends in the 30 days prior to study visits in which it was determined that a systemic lupus erythematosus (SLE) flare was present (flare visit) or not (no flare visit). Fever was defined as study fever (oral temperature >99.6°F) or a personal fever (oral temperature ≥ the top 10% of oral temperatures for that person). There is no difference in fever trends prior to flare visits compared to no flare visits (P = 0.41 for study fever,P = 0.69 for personal fever). Kidney International 2005 68, 747-759DOI: (10.1016/S0085-2538(15)50895-8) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Response of systemic lupus erythematosus (SLE) fever to glucocorticoid therapy. In a retrospective analysis, each patient was ascertained to have SLE fever (see case studies). The symbols identify the individual cases with SLE fever, which described in the case studies. Kidney International 2005 68, 747-759DOI: (10.1016/S0085-2538(15)50895-8) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Response of infection fever to glucocorticoid therapy. In a retrospective analysis, each patient was ascertained to have infection fever (see case studies). The symbols identify the individual cases with infection fever described in the case studies. Each of these patients was receiving moderate or higher steroid doses for 3 or more days at the time these observations were made. The data shown are typical of the oral temperatures displayed by these patients during their period of fever. At no point did the patients with the infection fever show a sustained reduction in oral temperature, as was consistently seen in the patients with systemic lupus erythematosus (SLE) fever (Figure 3.). Kidney International 2005 68, 747-759DOI: (10.1016/S0085-2538(15)50895-8) Copyright © 2005 International Society of Nephrology Terms and Conditions